Bristol-Myers Squibb Company (BMY) Holdings Held by Barbara Oil Co.
Barbara Oil Co. held its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,000 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Bristol-Myers Squibb accounts for approximately 1.7% of Barbara Oil Co.’s portfolio, making the stock its 18th largest holding. Barbara Oil Co.’s holdings in Bristol-Myers Squibb were worth $2,340,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of the business. State Street Corp raised its stake in Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares in the last quarter. Jennison Associates LLC raised its position in shares of Bristol-Myers Squibb by 5.4% in the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after buying an additional 1,184,652 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after buying an additional 2,451,390 shares in the last quarter. Legal & General Group Plc raised its position in shares of Bristol-Myers Squibb by 2.7% in the 2nd quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock valued at $469,802,000 after buying an additional 217,920 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Bristol-Myers Squibb by 3.2% in the 2nd quarter. Swiss National Bank now owns 6,111,570 shares of the biopharmaceutical company’s stock valued at $340,537,000 after buying an additional 189,900 shares in the last quarter. Institutional investors and hedge funds own 68.97% of the company’s stock.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.43 on Friday. The stock has a market cap of $100,542.48, a P/E ratio of 20.75, a P/E/G ratio of 2.42 and a beta of 1.18. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the firm posted $0.77 earnings per share. research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.
Several brokerages have recently commented on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group Inc restated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price for the company. in a research report on Thursday, September 28th. Finally, Cowen Inc set a $65.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $64.93.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-holdings-held-by-barbara-oil-co/1727247.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.